Clinical trials · New York, NY
Non-Muscle Invasive Bladder Urothelial Carcinoma clinical trials in New York
We’re tracking 15 recruiting non-muscle invasive bladder urothelial carcinoma studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
New York, New YorkAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
New York, New YorkAges 18 years+ - NCT06571708RecruitingPhase 2
Chemo plus immunotherapy for muscle-invasive bladder cancer
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
New York, New YorkAges 18 years+ - NCT07206225RecruitingPhase 1
Study of PF-08052667 in non-muscle invasive bladder cancer
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
New York, New YorkAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
New York, New YorkAges 18 years+ - NCT06668493RecruitingPhase 1/Phase 2
A virus-based treatment for low-grade upper tract bladder cancer
This trial tests a new drug, nadofaragene firadenovec, which uses a harmless virus to deliver a signal that helps your immune system fight low-grade cancer in the upper part of the urinary tract (the kidney area). It's given directly into the kidney through a small tube, and may avoid more invasive surgery.
New York, New YorkAges 18 years+ - NCT07673016Recruiting
Collecting urine to test a new bladder cancer detection method
This study collects urine samples to test UroAmp, a new genetic test that may help detect and monitor bladder cancer. It is for people with bladder cancer or blood in urine who want to help improve cancer detection.
New York, New YorkAges 18 years+ - NCT05126472RecruitingPhase 1/Phase 2
Study of 2141-V11 for bladder cancer that did not respond to standard treatment
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
New York, New YorkAges 18 years+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
New York, New YorkAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
New York, New YorkAges 18 years+ - NCT06995677RecruitingPhase 2
Study of TYRA-300 for bladder cancer that has not spread into muscle
This trial tests a new pill, TYRA-300, for people with a certain type of early-stage bladder cancer that has a specific genetic change (FGFR3). The goal is to see if it can help by targeting the cancer cells and possibly avoiding more invasive treatments.
New York, New YorkAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
New York, New YorkAges 18 years+ - NCT06503614RecruitingPhase 2
Durvalumab plus monalizumab for non-invasive bladder cancer
This study tests two immunotherapy drugs (durvalumab and monalizumab) in people with a type of bladder cancer that hasn't spread into the deep muscle layer. The goal is to see if this combination can help control the cancer and prevent it from coming back, possibly avoiding the need for bladder removal.
New York, New YorkAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Hackensack, New JerseyAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Voorhees Township, New JerseyAges 18 years+
Hear when a new Non-Muscle Invasive Bladder Urothelial Carcinoma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Non-Muscle Invasive Bladder Urothelial Carcinoma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting non-muscle invasive bladder urothelial carcinoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 6 studies
- Memorial Sloan Kettering Bergen · 4 studies
- Memorial Sloan Kettering Monmouth · 4 studies
- Memorial Sloan Kettering Nassau · 4 studies
- Memorial Sloan Kettering Westchester · 4 studies
- Atlantic Health System · 3 studies
- Memorial Sloan Kettering Basking Ridge · 3 studies
- Rutgers Cancer Institute of New Jersey · 3 studies
What taking part in a non-muscle invasive bladder urothelial carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting non-muscle invasive bladder urothelial carcinoma studies in New York.
Common questions
- Are there non-muscle invasive bladder urothelial carcinoma clinical trials near New York?
- Yes. We're currently tracking 15 recruiting non-muscle invasive bladder urothelial carcinoma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non-muscle invasive bladder urothelial carcinoma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non-muscle invasive bladder urothelial carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non-muscle invasive bladder urothelial carcinoma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.